• L-Plate Retiree
  • Posts
  • Hormone Therapy and Heart Risk: What a 12-Year Study of Women Found

Hormone Therapy and Heart Risk: What a 12-Year Study of Women Found

A conference study of 52,330 Israeli women who started hormone therapy at 45 to 59 found no link to heart attack, stroke, clots or early death.

In partnership with

because retirement doesn’t come with a manual

Make connection part of your routine.

Take ZOLEO on your next hike for messaging and “I’m OK” check-in messages beyond cell coverage. Save 20% on a regularly priced ZOLEO Satellite Communicator with code STAYCONNECTED20.

Not valid on sale-priced devices or with other discounts. Valid outside promotional sale periods.

Software stocks slumped, rate-hike talk grew louder, and the Dow fell 849 points before Nvidia reported.

The quick scan: Tuesday was a broad, heavy session. All three major indexes fell, the Dow by the most, and the S&P 500 closed at a reported five-month low. Software led the selling, Fed officials kept rate rises in the conversation, and the VIX climbed to about 25.5. Nvidia reported after the bell, outside Tuesday's figures.

S&P 500: -1.03% to 7,340.53 – lost 76.06 points, with selling spread well beyond technology.
Dow Jones: -1.64% to 50,759.42 – fell 848.75 points, the steepest drop of the three.
NASDAQ: -0.74% to 24,328.38 – fell 181.37 points, holding up better despite the software slide.

What's driving it: Salesforce fell more than 9%, with Intuit and ServiceNow each down more than 6%, as doubts about AI spending hung over software ahead of Nvidia's results. Selling picked up through the afternoon. St. Louis Fed President Alberto Musalem argued for rate rises sooner, and New York Fed President John Williams, while arguing against an outsized move, offered no hint of cuts. October retail sales rose 0.2%, slightly ahead of expectations. The VIX rose about 11% to 25.46.

Bottom line: The part to watch is not the 849 points but the rate-hike talk, which shapes what cash and bonds pay and how stocks are valued over months, not hours. For L-Plate Retirees, judge your portfolio over years, keep enough cash to sleep well, and let after-hours headlines settle before reacting.

Glowing skin, now 25% off this Black Friday

If glowing, radiant skin is on your wishlist, it's time to discover the BON CHARGE Red Light Face Mask.

Designed to make your skincare and wellness routine that little bit easier, the mask combines 630nm red light and 850nm near infrared light to help promote a more youthful-looking complexion, smoother skin texture and a more even-looking skin tone. Just 10 minutes a day is all it takes to incorporate this simple step into your routine. It's lightweight, portable and contours perfectly to your face, making it easy to use whether you're relaxing at home or traveling.

I love that BON CHARGE creates premium wellness products grounded in science and driven by purpose.

BON CHARGE is having a Black Friday Sale, offering 25% off sitewide. Click the link to shop your favorites, with the discount automatically applied at checkout.

Does Hormone Therapy Put the Heart at Risk? A Big Study Found No Link

The scoop: Picture two women in their early fifties, sitting a few chairs apart in a gynaecologist's waiting room. Same age, much the same blood pressure, similar cholesterol, neither of them a smoker. One walks out with a prescription for hormone therapy to ease her menopausal symptoms. The other decides to soldier on without it. Now fast-forward a decade or so and ask a simple question: did the first woman's heart pay a price for that choice?

That, in essence, is the question behind a study presented at the American Heart Association's Scientific Sessions 2026, held in Chicago from 6 to 9 November. The AHA news release sets out what a team led by Ronen Arbel, PhD, of Clalit Health Services and Sapir College in Israel, found when they followed tens of thousands of women for years. One caveat belongs right at the front: this is a conference abstract, not a published, peer-reviewed paper. Everything below should be read as preliminary.

A question many women carry quietly

If you have gone through menopause, or lived alongside someone who has, you may know the conversation. The hot flushes are miserable, the nights are broken, but is the relief worth whatever it might do to the heart? It is the kind of question people often take home and turn over at the kitchen table rather than ask out loud in a ten-minute appointment.

For readers who are men, and plenty of you are, this is not someone else's issue. Many of you will have sat beside a partner, sister or friend weighing exactly this decision. Knowing what the research does and does not say is a good way to be useful company in that conversation.

Who was studied

The researchers used health records from Clalit, a large Israeli health organisation. They identified 52,330 women aged 45 to 59 who had no history of heart disease, blood clots or cancer. About half started hormone therapy, mainly by mouth or by patch, with some using a gel. The other half had visited a gynaecologist but never started it.

That comparison group is a thoughtful choice. Every woman in it had been to the same kind of appointment, so the study is not simply comparing women who saw a doctor with women who did not. According to Healio, which reported on the presentation, the two groups were also matched on age, body mass index, blood pressure, blood fats such as cholesterol, diabetes, smoking and socioeconomic status.

Records were reviewed for up to 23 years, and the average follow-up was 12 years. That is a long stretch of real life: careers winding down, children leaving home, the slow and dignified surrender to reading glasses.

What they found

Over that time, 2,311 women who used hormone therapy (4.4 percent) had a heart attack, stroke or related heart disease, compared with 2,383 women who did not (4.6 percent). Healio reported the rates as 7.82 versus 7.99 per 1,000 person-years, with an adjusted hazard ratio of 0.98.

A hazard ratio is simply a way of comparing how often something happens in one group against another. A figure of 1.00 means no difference. A figure of 0.98, with a confidence range running from 0.93 to 1.04, sits right on top of "no meaningful difference" in either direction.

The other outcomes told the same story. Death before age 80 occurred in 659 women on hormone therapy (1.3 percent) and 653 who did not use it (1.2 percent), a hazard ratio of 1.03. Blood clots were recorded in 174 versus 175 women, 0.33 percent in each group, a hazard ratio of 1.01. A combined measure came out at exactly 1.00. The picture did not change according to whether women took hormone therapy by mouth, by patch or as a gel.

If you were hoping for a dramatic twist, there isn't one. Sometimes the most useful headline in health research is the dull one: no difference found.

What the lead researcher wants you to hear

It would be easy to read "no link" and leap to a bigger conclusion. Dr Arbel closes that door himself. As Healio reported, he said: "HT should be prescribed to treat menopausal symptoms – not as cardiovascular prevention."

In other words, this is not a study suggesting hormone therapy is good for the heart. It found no difference in heart outcomes between the two groups. Those are two very different statements, and only the second is what the data show.

Stacey E. Rosen, MD, an independent expert quoted in the AHA release, said the study adds to growing evidence that today's options may not increase heart risk. Note the word "may". It is a careful word, chosen by a careful person.

What this study cannot tell us

Quite a lot, and the limits matter as much as the result.

This is an observational study. It looks back at what happened to women who made different choices; it did not randomly assign anyone to hormone therapy. Matching helps, but it cannot account for everything. Exercise, diet, other health conditions and how severe women's symptoms were could not be measured, and any of them could be quietly shaping the numbers. Women were also grouped by the first type of hormone therapy they used.

The findings apply only to a specific group: women who started hormone therapy between 45 and 59 and had no history of heart disease, blood clots or cancer. They say nothing about women who started later, or women with those conditions. This was an Israeli cohort, so the results cannot simply be carried over to women in Singapore, Malaysia, the US or anywhere else. And this study was about women only.

Finally, because this is a conference abstract, the full methods and data have not yet been through peer review. Findings presented at meetings can change once the complete paper is examined.

Why it still matters

Worry has a way of hardening into fact when nobody revisits it. A study like this does not settle anything on its own, but it adds a long-running, carefully matched piece of evidence to a conversation many women have found unsettling.

The practical point is modest, and it is the right one. If hot flushes, broken sleep or other menopausal symptoms are affecting your life, any decision about treatment belongs to you and your doctor, made on your own history. This study is one useful thing to bring into that room. It is not a reason to start, stop or change anything by yourself.

Good research rarely shouts. This one speaks quietly. Listen anyway.

Actionable takeaways for L-Plate Retirees:

  • Read this as early research. It was presented as a conference abstract in November 2026 and has not been peer reviewed. The full paper is not yet published, so the details behind the figures cannot be checked. Early findings can shift once everything is examined, so hold this one loosely and look out for the full paper.

  • Keep "no link" and "good for the heart" apart. The study found no difference in heart attack, stroke, blood clots or death before 80 between the two groups. It did not find that hormone therapy helps the heart, and the lead researcher was clear that hormone therapy is for menopausal symptoms, not heart prevention. If a friend or a headline blurs those two ideas, gently unblur them.

  • Check whether the findings describe you. The women studied started hormone therapy between 45 and 59, had no history of heart disease, blood clots or cancer, and lived in Israel. If you started later, have one of those conditions, or live elsewhere, treat this as background reading rather than a prediction about you.

  • Bring questions, not conclusions, to your doctor. Nothing here is a reason to start, stop or change hormone therapy on your own. If you are weighing it up, ask your doctor how your own history, symptoms and risks fit the picture. Jot your questions on paper beforehand, because a short appointment has a way of chasing them out of your head.

  • Remember what matching can and cannot do. The two groups were matched on age, weight, blood pressure, cholesterol, diabetes, smoking and socioeconomic status. That is careful work, but exercise, diet, other conditions and symptom severity were not measured. A matched comparison narrows the gap between groups; it does not close it.

  • If it is not your decision, be good company. Many readers will be a partner, sibling or friend rather than the person deciding. The most helpful thing is often to listen, read the research calmly and encourage the conversation with a doctor, rather than offering a verdict of your own.

Your Turn: 
If you have weighed up hormone therapy, or watched someone close to you do it, what information do you wish you had at the time?
When a study finds "no difference" rather than a dramatic result, do you trust it more or less, and why?
What is one health worry you have carried for years but never checked against current evidence?

👉 Hit reply and share your thoughts – your answers could inspire fellow readers in future issues.

☕ If this issue helped you see the gap between "not linked to heart risk" and "good for the heart", consider shouting L-Plate Retiree a coffee on Ko-fi. Your support keeps us reading the fine print behind health headlines so the rest of the week can be spent on more enjoyable things.

Eat well without any effort.

Getting the nutrition you deserve doesn’t need to take up all your time. CookUnity delivers fresh dishes handcrafted by award-winning chefs, ready to heat in minutes. Build a custom menu for your entire week, so you can spend your evenings on your terms—not scrubbing pans. Skip, pause, or change your plan size anytime.

The L-Plate Retiree community is just beginning, and we’re figuring this out together–no pretense, no judgment, just honest conversation about navigating this next chapter.

Subscribe now, or share it with a friend, to get weekly insights, practical tips, and the occasional laugh to help you prepare for or thrive in retirement. Unlike other newsletters that assume you already know everything, we keep it simple and human.

And if today’s lifestyle musings brightened your day, you can toss a coffee into our Ko-fi tip jar ☕. Think of it like leaving a tip for your favourite busker – only this busker writes about retirement.

Because retirement doesn’t come with a manual… but now it does come with this newsletter.

The L-Plate Retiree Team

(Disclaimer: While we love a good laugh, the information in this newsletter is for general informational and entertainment purposes only, and does not constitute financial, health, or any other professional advice. Always consult with a qualified professional before making any decisions about your retirement, finances, or health.)

Reply

or to participate.